Cancer SIGVAR

Cancer SIGVAR interprets germline variants in hereditary cancer-related genes using adapted ClinGen Sequence Variant Interpretation Working Group and ACMG/AMP recommendations to support clinical classification.

Key Features:

• Input format: Accepts VCF files as input for variant interpretation.
• Adapted ACMG/AMP criteria: Implements 48 variant-interpretation criteria adapted from ClinGen SVI WG and ACMG/AMP recommendations, expanded from an initial 28 criteria.
• Operation modes: Provides a fully automated mode applying 21 criteria and a semiautomated mode utilizing all 48 criteria.
• Benchmarking datasets: Validated against ClinVar and CLINVITAE and two in-house benchmark databases totaling 911 variants.
• Performance metrics: Reported average pathogenicity assessment accuracy of 93.71%, benign assessment accuracy of 79.38%, and semiautomated classification consistency of 98.35% on the in-house benchmarks.
• Comparative analysis: Includes direct comparisons with InterVar and PathoMAN to evaluate differences in criteria application and implementation strategies.

Scientific Applications:

• Germline variant classification: Classification of clinical significance for germline variants in hereditary cancer-related genes.
• Genetic counseling and clinical interpretation: Support for variant classifications used in genetic counseling and clinical decision-making for hereditary cancer.
• Method and tool evaluation: Benchmarking and comparative evaluation of variant-interpretation criteria and tools using ClinVar, CLINVITAE, and in-house datasets.

Methodology:

Accepts VCF input and applies adapted ClinGen SVI WG/ACMG-AMP criteria expanded to 48 rules; operates in a fully automated mode using 21 criteria or a semiautomated mode using all 48 criteria; validated against ClinVar, CLINVITAE, and two in-house benchmark databases (911 variants) and compared with InterVar and PathoMAN.